AI-generated summary
This randomized controlled trial studied multiwavelength photobiomodulation in people with nonexudative (dry) age-related macular degeneration, comparing treatment with sham. The authors report a statistically significant between-group difference in best-corrected visual acuity at 13 months and fewer new cases of geographic atrophy in the treatment group, with a favorable safety profile. Findings come from an interim analysis of a longer study.
- Participants
- 100
- Who or what was studied
- Adults with nonexudative (dry) age-related macular degeneration, 100 subjects (148 eyes) randomized
- Wavelengths
- 590, 660, 850 nm
- Limits stated in the abstract
- The abstract reports a 13-month interim analysis of a 24-month study, and the between-group visual acuity difference is small at 2.4 letters.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.lww.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 850 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Age-related macular degeneration, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.